We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

8 hedge funds and large institutions have $129K invested in ABVC BioPharma in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

61% more capital invested

Capital invested by funds: $79.8K → $129K (+$48.7K)

0.9% less ownership

Funds ownership: 1.94% → 1.05% (-0.9%)

11% less funds holding

Funds holding: 9 → 8 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
8
Holders Change
-1
Holders Change %
-11.11%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$42.6K
2
Citadel Advisors
Citadel Advisors
Florida
+$13.6K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$10.5K
4
Wells Fargo
Wells Fargo
California
+$2

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$21K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.84K
3
JP Morgan Chase
JP Morgan Chase
New York
-$2

ABVC Hedge Fund Activity: Q4 2023 in Review

8 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2023, worth a combined $129K — up 61% from $79.8K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ABVC and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $42.6K. The largest seller was Virtu Financial, exiting entirely with an estimated $21K sold.

  • 8 institutional investors held ABVC BioPharma (ABVC) as of Q4 2023, down from 9 in Q3 2023.
  • Funds reported $129K of ABVC BioPharma stock for Q4 2023, up 61% quarter-over-quarter.
  • 1 fund opened new ABVC BioPharma positions in Q4 2023 and 2 closed out, a net change of -1 holder.
  • The largest ABVC BioPharma buyer in Q4 2023 was Renaissance Technologies, an estimated $42.6K added.
  • The largest ABVC BioPharma seller in Q4 2023 was Virtu Financial, an estimated $21K sold.

Based on aggregated 13F filings for Q4 2023.